# SPRO — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-07-21. Informational only, not financial advice.

**Recommendation:** HOLD

**Scores (0–100):** Overall 3.9 · Fundamentals 3.8 · Technicals 1.8 · Growth 6 · Risk 8.5

## Summary

SPRO is an $83M micro-cap that just printed a fresh 52-week low at $1.41 despite two transformative deals (KKR $105M non-dilutive royalty + Innovent SP001/CD40L in-license up to $1.1B), a textbook signal that the tape is treating optionality as a liability rather than an asset. Q1'26 revenue collapsed 95% Q/Q to $258K, confirming there is no recurring business — this is a pure clinical/royalty option trading on execution, cash burn, and CD40L class safety. With RSI 23.6, price ~40% below all major SMAs, short float rising to 6.7%, and the 1-week model assigning 0% bullish probability, the risk/reward is asymmetric to the downside into the Aug 11 print.

## Price targets (6-month horizon)

- Bear: $1.10
- Base: $1.55
- Bull: $2.10

## News context

The two headline catalysts are also the two most important signals: (1) the July 15 Innovent global-ex-China license for IBI355 (CD40L antibody) worth up to $1.1B in milestones, and (2) the July 14 $105M non-dilutive royalty financing from KKR-owned HealthCare Royalty monetizing future Utebzi cash flows. In a healthy tape, either would be a re-rating event; instead the stock is down ~34% on the week. The 8-K filed 7/14 explicitly flags large upfront and milestone payments to Innovent as a financial impact — the market appears to be pricing the Innovent outflows as a near-term cash drag that may outpace Utebzi royalty inflows, with SP001 Phase 2 readouts not expected until ~2027. Sell-side is quiet (Recom 3.0, target $4 looks stale), and social sentiment (100% bullish of the tagged messages) is a mild contrarian negative — retail is buying capitulation while insiders/institutions are not.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/spro-ai-stock-forecast-fb02990e927578fc3b188a9fbfc35e38
- AI-generated; model outputs can be wrong. Not financial advice.